YOUR SEARCH FOR Text 165 RESULTS
61 of Total
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… results, and provides a status update on the Company’s clinical development portfolio. “Our … dermatitis in the United States,” said Hervé Hoppenot , Chief Executive Officer, Incyte . …
62 of Total
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… results, and provides a status update on the Company’s clinical development portfolio. “The … and satisfaction remain strong,” said Hervé Hoppenot , Chief Executive Officer, Incyte . …
63 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… progress across our R&D pipeline," said Hervé Hoppenot , Chief Executive Officer, Incyte . … and TGFβR2xPD-1 in solid tumors. Key Recent Company Updates A bioequivalence study of …
64 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… acquisition of Escient Pharmaceuticals completed – $2.0 billion share repurchase … for Jakafi ® (ruxolitinib)," said Hervé Hoppenot , Chief Executive Officer, Incyte . …
65 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… months of U.S. launch demonstrating strong commercial execution and high patient need – … to achieve our full year objectives," said Hervé Hoppenot , Chief Executive Officer, Incyte . …
66 of Total
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… results, and provides a status update on the Company’s clinical development portfolio. "Our … Opzelura for vitiligo in Europe.” said Hervé Hoppenot , Chief Executive Officer, Incyte . …
67 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… results, and provides a status update on the Company’s clinical development portfolio. "In … associated with chronic GVHD," said Hervé Hoppenot , Chief Executive Officer, Incyte . …
68 of Total
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance
… guidance and provides a status update on the Company’s clinical development portfolio. "We … adoption in vitiligo has been strong,” said Hervé Hoppenot , Chief Executive Officer, Incyte . …
69 of Total
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… results, and provides a status update on the Company’s clinical development portfolio. "We … and vitiligo in the United States ," said Hervé Hoppenot , Chief Executive Officer, Incyte . …
70 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… guidance and provides a status update on the Company’s research and development portfolio. … of Opzelura ® (ruxolitinib) cream," said Hervé Hoppenot , Chief Executive Officer, Incyte . …